SELLAS Life Sciences Announces Completion of Enrollment in Phase 2 Randomized Controlled Clinical Study of Nelipepimut-S Plus Trastuzumab in High-risk, High-expression HER2 Breast Cancer Patients
Data Expected in Fourth Quarter of 2019 Second Clinical Study of Nelipepimut-S Plus Trastuzumab After Recently Announced Positive Phase 2b […]